NCNA
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Jul 18 closing price
Capitalization
18.2M
PALI
Price
$0.75
Change
-$0.00 (-0.00%)
Updated
Jul 18 closing price
Capitalization
3.75M
Interact to see
Advertisement

NCNA vs PALI

Header iconNCNA vs PALI Comparison
Open Charts NCNA vs PALIBanner chart's image
NuCana
Price$0.05
Change-$0.00 (-0.00%)
Volume$67.88M
Capitalization18.2M
Palisade Bio
Price$0.75
Change-$0.00 (-0.00%)
Volume$57.52K
Capitalization3.75M
NCNA vs PALI Comparison Chart in %
Loading...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NCNA vs. PALI commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NCNA is a Hold and PALI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (NCNA: $0.05 vs. PALI: $0.75)
Brand notoriety: NCNA and PALI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NCNA: 41% vs. PALI: 22%
Market capitalization -- NCNA: $18.2M vs. PALI: $3.75M
NCNA [@Biotechnology] is valued at $18.2M. PALI’s [@Biotechnology] market capitalization is $3.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NCNA’s FA Score shows that 0 FA rating(s) are green whilePALI’s FA Score has 1 green FA rating(s).

  • NCNA’s FA Score: 0 green, 5 red.
  • PALI’s FA Score: 1 green, 4 red.
According to our system of comparison, PALI is a better buy in the long-term than NCNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NCNA’s TA Score shows that 2 TA indicator(s) are bullish while PALI’s TA Score has 6 bullish TA indicator(s).

  • NCNA’s TA Score: 2 bullish, 3 bearish.
  • PALI’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, PALI is a better buy in the short-term than NCNA.

Price Growth

NCNA (@Biotechnology) experienced а -4.98% price change this week, while PALI (@Biotechnology) price change was -0.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NCNA($18.2M) has a higher market cap than PALI($3.75M). PALI YTD gains are higher at: -54.533 vs. NCNA (-95.992). PALI has higher annual earnings (EBITDA): -13.13M vs. NCNA (-16.98M). PALI has more cash in the bank: 7.23M vs. NCNA (3.95M). PALI has less debt than NCNA: PALI (58K) vs NCNA (173K). NCNA (0) and PALI (0) have equivalent revenues.
NCNAPALINCNA / PALI
Capitalization18.2M3.75M486%
EBITDA-16.98M-13.13M129%
Gain YTD-95.992-54.533176%
P/E RatioN/A0.02-
Revenue00-
Total Cash3.95M7.23M55%
Total Debt173K58K298%
FUNDAMENTALS RATINGS
NCNA vs PALI: Fundamental Ratings
NCNA
PALI
OUTLOOK RATING
1..100
1012
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
9964
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PALI's Valuation (18) in the null industry is in the same range as NCNA (36) in the Biotechnology industry. This means that PALI’s stock grew similarly to NCNA’s over the last 12 months.

PALI's Profit vs Risk Rating (100) in the null industry is in the same range as NCNA (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to NCNA’s over the last 12 months.

PALI's SMR Rating (99) in the null industry is in the same range as NCNA (99) in the Biotechnology industry. This means that PALI’s stock grew similarly to NCNA’s over the last 12 months.

PALI's Price Growth Rating (64) in the null industry is somewhat better than the same rating for NCNA (99) in the Biotechnology industry. This means that PALI’s stock grew somewhat faster than NCNA’s over the last 12 months.

PALI's P/E Growth Rating (100) in the null industry is in the same range as NCNA (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to NCNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NCNAPALI
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 11 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPG40.390.77
+1.94%
Ascentage Pharma Group
ZS288.722.43
+0.85%
Zscaler
PASG5.56N/A
N/A
Passage Bio Inc
BLND3.37-0.15
-4.26%
Blend Labs
TIL26.10-1.60
-5.78%
Instil Bio

NCNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NCNA has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCNA
1D Price
Change %
NCNA100%
+1.92%
CDTX - NCNA
93%
Closely correlated
+6.79%
NBY - NCNA
92%
Closely correlated
+2.00%
WINT - NCNA
92%
Closely correlated
+13.33%
RNAC - NCNA
92%
Closely correlated
-5.51%
TAOX - NCNA
92%
Closely correlated
+7.55%
More

PALI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PALI has been closely correlated with CDTX. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
+0.56%
CDTX - PALI
82%
Closely correlated
+6.79%
WINT - PALI
81%
Closely correlated
+13.33%
TAOX - PALI
81%
Closely correlated
+7.55%
NCNA - PALI
81%
Closely correlated
+1.92%
NBY - PALI
80%
Closely correlated
+2.00%
More